Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04994704
Other study ID # 3-2021-0216
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date July 12, 2023

Study information

Verified date July 2023
Source Gangnam Severance Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. In addition, it has no injection pain and infusion syndrome compared with propofol. In particular, there is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia in the cervical spine surgery with intraoperative neurophysiological monitoring.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date July 12, 2023
Est. primary completion date July 12, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: - Adult patients who aged 20-70 years with ASA-PS 1-3, - diagnosed of ossification of the posterior longitudinal ligament or cervical spondylotic myelopathy - intraoperative neurophysiological monitoring. Exclusion Criteria: - Tolerance or hypersensitivity to benzodiazepine or propofol - Dependence or addiction to psychotropic drugs or alcohol - Pregnant women, subjects who lack the ability to make decisions and susceptible to voluntary participation decisions

Study Design


Related Conditions & MeSH terms

  • Patients Undergoing Spine Surgery

Intervention

Drug:
Propfol group
Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
Remimazolam group
Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.

Locations

Country Name City State
Korea, Republic of GangnamSeverance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Gangnam Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference of QoR-15 scores between two groups (propofol vs. remimazolam) The difference of scores in the Quality of Recovery (QoR)-15 survey.Minimum value: 0, Maximum value: 150, higher scores means better. postoperative day 1
See also
  Status Clinical Trial Phase
Recruiting NCT03644407 - Galeazzi Spine Surgery RegistryGaleazzi Spine Registry: Prospective Study for Clinical Monitoring
Completed NCT01877876 - Assessing the Accuracy of the RevK Sensor N/A
Completed NCT01750554 - The Influence of a Bupivacaine Digital Nerve Block Using Rev G. N/A